Eli Lilly (NYSE:LLY) Speeds Up Weight Loss Drug Data Release
Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...
Eli Lilly records over twofold rise in diabetes/ obesity drugs in Q4
Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...
Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...
devdiscourse7h
Wall Street's Brief Respite Amid Economic Uncertainties
Wall Street saw slight gains on Thursday with positive earnings from major companies such as Eli Lilly and Tapestry. Despite ...
Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...
Lilly Forecasts 2025 Profit Largely Above Estimates on Weight-Loss Drug Strength
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...
devdiscourse8h
Wall Street in Limbo Amidst Trump's Trade Policies and Corporate Forecasts
Wall Street was poised for a flat start as investors analyzed earnings from major companies like Honeywell and anticipated ...
BioPharma Dive4h
Eli Lilly’s earnings, shares lifted by obesity drug sales
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Eli Lilly’s Results Already Disappointed the Street. More Details Come Thursday.
The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.